Key facts
- Santero Therapeutics’s last known valuation is $13.3M (Mar 2025).
- It has raised $9.9M; the latest was Early Stage VC ($8.6M) in Mar 2025.
- Notable investors include SambrInvest, Société Fédérale de Participations et d'Investissement, Université Libre de Bruxelles, Newton BioCapital, Pierre Drion — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Santero Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Santero Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Santero Therapeutics
Developer of antibiotics designed to fight multiple resistant pathogens. The company provides medicines and inhibitors for the treatment of multidrug-resistant infections with the benefit of prolonged efficacy before new resistance develops, enabling patients to get treatments with better-tolerated drugs.
- Sector
- Healthcare
- HQ
- Charleroi, Belgium
- Founded
- 2021
- Employees
- 22
- Website
- santero.be/
- Ownership
- Privately Held (backing)
Santero Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Santero Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Santero Therapeutics in its N-PORT filings yet. We sweep new filings monthly.